TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8176554

Group type: EXPERIMENTAL
Intervention: Flutter device
Number of subjects: 18

Group type: COMPARATOR
Intervention: Voluntary coughing
Number of subjects: 18

Group type: COMPARATOR
Intervention: Postural drainage
Number of subjects: 18
Study: 3299495

Group type: EXPERIMENTAL
Intervention: Trihexphenidyl (Artane)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30102667

Group type: EXPERIMENTAL
Intervention: V-pattern injection (group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Middle horizontal pattern injection (group 2)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High horizontal pattern injection (group 3)
Number of subjects: 45
Study: 28219752

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wakefulness period (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit knowledge acquisition before sleep
Number of subjects: 0
Study: 26156077

Group type: EXPERIMENTAL
Intervention: High palmitate (HPA) diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low palmitate/high oleic acid (HOA) diet
Number of subjects: 17
Study: 24140296

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol (PRO)
Number of subjects: 0
Study: 20949623

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV6/11/16/18 vaccine
Number of subjects: 17622

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17622

Group type: EXPERIMENTAL
Intervention: Both groups (vaccine and placebo)
Number of subjects: 17622
Study: 18716740

Group type: EXPERIMENTAL
Intervention: Bifilac (probiotic)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17288230

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) with significant restriction of the number of cigarettes smoked per day
Number of subjects: 0
Study: 15248628

Group type: EXPERIMENTAL
Intervention: Alfentanil 3 microg kg(‐1) min(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Esmolol 1 mg kg(‐1) min(‐1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Clonidine 3 microg kg(‐1)
Number of subjects: 45
Study: 10966884

Group type: EXPERIMENTAL
Intervention: Dairy foods (various types including milk and yogurt)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Stronger-evidence studies of dairy foods
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dairy foods in <30-y-olds
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dairy foods in 30-50-y-olds
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Dairy foods in >50-y-olds
Number of subjects: 57
Study: 8956395

Group type: EXPERIMENTAL
Intervention: Lidocaine-clonidine retrobulbar block (3-4 mL of 2% lidocaine with clonidine 2 micrograms/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lidocaine retrobulbar block (3-4 mL of 2% lidocaine with 1 mL saline)
Number of subjects: 60
Study: 1373231

Group type: EXPERIMENTAL
Intervention: Somatostatin (125 micrograms/hour)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 3891900

Group type: EXPERIMENTAL
Intervention: Pre-exposure immune serum globulin (ISG)
Number of subjects: 802

Group type: COMPARATOR
Intervention: No pre-exposure immune serum globulin (ISG)
Number of subjects: 802
Study: 31647836

Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily (BID) for fifteen days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Rifabutin 300 mg once daily (QD) added on day six
Number of subjects: 14
Study: 29702070

Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic-based rehabilitation
Number of subjects: 0
Study: 27107307

Group type: EXPERIMENTAL
Intervention: Semi-rigid Subortholene orthoses
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Soft EVA orthoses
Number of subjects: 9
Study: 24382410

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Medical rate control
Number of subjects: 50
Study: 22459124

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) approach
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional surgical approach
Number of subjects: 44
Study: 20145562

Group type: EXPERIMENTAL
Intervention: Cystine (700 mg) and theanine (280 mg) supplementation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (cellulose 950 mg and glutamate 30 mg)
Number of subjects: 15
Study: 19056532

Group type: EXPERIMENTAL
Intervention: Infliximab (0.8 mg/ml)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (without Infliximab)
Number of subjects: 97
Study: 16837737

Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg daily for 15 days plus serratiopeptidase 10 mg daily for 30 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 50

Group type: COMPARATOR
Intervention: Post-treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Treatment response
Number of subjects: 50
Study: 14984226

Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: zolmitriptan 2.5 mg
Number of subjects: 1587

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1587
Study: 10664830

Group type: EXPERIMENTAL
Intervention: Ketamine (intravenous bolus 0.26 mg/kg followed by infusion of 0.65 mg/kg/hour)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 22
Study: 9134412

Group type: EXPERIMENTAL
Intervention: Fetal oxygen saturation monitoring (pulse oximeter)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8403806

Group type: EXPERIMENTAL
Intervention: Oral glucose ingestion (75 g) in hypertensive patients
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral glucose ingestion (75 g) with potassium chloride supplementation in hypertensive patients
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral glucose ingestion (75 g) in normotensive control subjects
Number of subjects: 16
Study: 3782648

Group type: EXPERIMENTAL
Intervention: 20 mg sublingual nifedipine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30722837

Group type: EXPERIMENTAL
Intervention: Yoga intervention group without yoga postures
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Yoga intervention group with yoga postures
Number of subjects: 75

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 75
Study: 26886370

Group type: EXPERIMENTAL
Intervention: Water protocol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Thickened liquids only
Number of subjects: 14
Study: 24842558

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg Q2W (with uptitration to 150 mg Q2W if LDL-C ≥70 mg/dL at Week 8)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W throughout the treatment period (in HIGH FH)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 22425218

Group type: EXPERIMENTAL
Intervention: New oral anticoagulants (NAs)
Number of subjects: 32144

Group type: COMPARATOR
Intervention: Rivaroxaban (40 mg QD)
Number of subjects: 32144

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 32144

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 32144
Study: 20574636

Group type: EXPERIMENTAL
Intervention: Standard Intervention (Pre‐post HIV counseling); N = 50
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (Standard + Body Wise Intervention); N = 50
Number of subjects: 100
Study: 18430172

Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% hydroquinone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glycolic acid peels alone (Control)
Number of subjects: 60
Study: 15867404

Group type: EXPERIMENTAL
Intervention: Low-Fat diet
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-Fat Plus diet
Number of subjects: 120

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 120
Study: 12651685

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (BIC, 1 M; n = 12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tris-hydroxymethyl aminomethane (THAM, 3 M; n = 12)
Number of subjects: 24
Study: 11804898

Group type: EXPERIMENTAL
Intervention: Primary unenhanced helical CT (protocol B)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Unenhanced radiography and sonography with helical CT in unclear cases (protocol C)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Combined sonography and radiography (protocol A)
Number of subjects: 96
Study: 10416732

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (individual daily sessions of 1 hour for up to 3 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive occupational therapy (control group)
Number of subjects: 0
Study: 7569830

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol replacement therapy plus norethisterone acetate 1 mg per day, oral, cyclically for 12 days monthly
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy
Number of subjects: 112
Study: 2341828

Group type: EXPERIMENTAL
Intervention: ESKIMO-3 (15 ml daily for 6 months)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: ESKIMO-3 (30 ml daily for 4 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 33
Study: 7246688

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided midtrimester amniocentesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard midtrimester amniocentesis without ultrasound
Number of subjects: 0
Study: 6376030

Group type: EXPERIMENTAL
Intervention: Dietary treatment with energy and carbohydrate restriction
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Glibenclamide and chlorpropamide
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Insulin treatment
Number of subjects: 38
Study: 31661346

Group type: EXPERIMENTAL
Intervention: Integrated Psychological Therapy (IPT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment as Usual (TaU)
Number of subjects: 40
Study: 29868916

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (cholecalciferol)
Number of subjects: 2994
Study: 27843084

Group type: EXPERIMENTAL
Intervention: Atropine 1%
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1%
Number of subjects: 49

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 49
Study: 24527596

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic fields (PEMFs) once a day for 30 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional drug therapy
Number of subjects: 43
Study: 22323376

Group type: EXPERIMENTAL
Intervention: Validating communication
Number of subjects: 28

Group type: COMPARATOR
Intervention: Invalidating communication
Number of subjects: 28
Study: 19996813

Group type: EXPERIMENTAL
Intervention: ketorolac tromethamine 0.4% (one drop twice a day for 2 weeks)
Number of subjects: 12

Group type: COMPARATOR
Intervention: artificial tear solution (placebo, used for 2 weeks)
Number of subjects: 12
Study: 18004596

Group type: EXPERIMENTAL
Intervention: Tolterodine 1-2 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Imipramine 25-50 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16897906

Group type: EXPERIMENTAL
Intervention: Live music therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Verbal interaction (Control)
Number of subjects: 14
Study: 14574083

Group type: EXPERIMENTAL
Intervention: ACEI perindopril
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ARB candesartan
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (without perindopril and candesartan)
Number of subjects: 36
Study: 10784228

Group type: EXPERIMENTAL
Intervention: 60 mg nateglinide (single oral dose, given 20 min prior to IGTT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 10
Study: 8769510

Group type: EXPERIMENTAL
Intervention: L-arginine hydrochloride infusion (0.5 g/kg for 30 minutes)
Number of subjects: 10
Study: 1563948

Group type: EXPERIMENTAL
Intervention: Autogenic relaxation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Autogenic plus progressive relaxation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 17
Study: 3902588

Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg at lunch, 400 mg at bedtime)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 107
Study: 31244692

Group type: EXPERIMENTAL
Intervention: Robin (16 weekly individual sessions + a minimum of 4 family sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (active control group)
Number of subjects: 30
Study: 30419893

Group type: EXPERIMENTAL
Intervention: Usual care plus the DATES text message intervention
Number of subjects: 572

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 572
Study: 25891220

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Venlafaxine-extended release
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nonremitters
Number of subjects: 80
Study: 24874737

Group type: EXPERIMENTAL
Intervention: Knocking down of the α‐synuclein gene
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Energy deprivation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3‐methyladenine or ATG5 knocking down
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T lymphocytes from patients with systemic lupus erythematosus
Number of subjects: 0
Study: 22851072

Group type: EXPERIMENTAL
Intervention: Propofol infusion with TCI vein pump (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remifentanil vein infusion with PCA pump (Group C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Non-anaesthesia (Group A)
Number of subjects: 120
Study: 20151090

Group type: EXPERIMENTAL
Intervention: Nutritional intervention program
Number of subjects: 393
Study: 18665819

Group type: EXPERIMENTAL
Intervention: 0.5% alcoholic chlorhexidine gluconate (alcoholic CG)
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: 2% aqueous chlorhexidine gluconate (aqueous CG)
Number of subjects: 631

Group type: COMPARATOR
Intervention: 10% aqueous povidone iodine (aqueous PI)
Number of subjects: 631
Study: 16422893

Group type: EXPERIMENTAL
Intervention: 10 degrees C saline
Number of subjects: 122

Group type: COMPARATOR
Intervention: 37 degrees C saline
Number of subjects: 122

Group type: COMPARATOR
Intervention: 15 degrees C saline
Number of subjects: 122

Group type: COMPARATOR
Intervention: 20 degrees C saline
Number of subjects: 122
Study: 12859114

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide for 1 h/day for 21 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide for 7 h/day for 21 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (nontreated specimens)
Number of subjects: 60
Study: 10649262

Group type: EXPERIMENTAL
Intervention: Intervention group (oral cancer screening)
Number of subjects: 59994

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 59994
Study: 8618580

Group type: EXPERIMENTAL
Intervention: Interferon alfa
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 103
Study: 1535816

Group type: EXPERIMENTAL
Intervention: 20 micrograms HBs antigen vaccine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Other hepatitis B vaccine
Number of subjects: 80
Study: 6150660

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg ketamine intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: 5.0 mg/kg thiopental intravenously
Number of subjects: 20
Study: 30243234

Group type: EXPERIMENTAL
Intervention: FES cycling exercise
Number of subjects: 11

Group type: COMPARATOR
Intervention: Passive leg cycling (PLC)
Number of subjects: 11
Study: 29201390

Group type: EXPERIMENTAL
Intervention: Positive Written Disclosure (PWD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral writing control
Number of subjects: 60

Group type: COMPARATOR
Intervention: No writing condition
Number of subjects: 60
Study: 26654250

Group type: EXPERIMENTAL
Intervention: PREPARE website and easy-to-read advance directive
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advance directive only (Control)
Number of subjects: 0
Study: 23569301

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (FOLFIRI or mFOLFOX6)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cetuximab plus chemotherapy (FOLFIRI or mFOLFOX6) with resection of liver metastases
Number of subjects: 138

Group type: COMPARATOR
Intervention: Chemotherapy alone without resection
Number of subjects: 138
Study: 21860843

Group type: EXPERIMENTAL
Intervention: Investigational drug (seven doses)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: COMPARATOR
Intervention: Active comparator
Number of subjects: 202
Study: 17936405

Group type: EXPERIMENTAL
Intervention: Spiral CT
Number of subjects: 2472

Group type: COMPARATOR
Intervention: Control (yearly clinical examination)
Number of subjects: 2472
Study: 16785190

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 92
Study: 12540116

Group type: EXPERIMENTAL
Intervention: OneGloss (OG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Super‐Snap system (SS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Robot Carbides (RC)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CompoSite Polishers (CS)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Finishing/polishing techniques (general)
Number of subjects: 32
Study: 10952804

Group type: EXPERIMENTAL
Intervention: Endoscopic haemostasis using single-modality treatments (injection agents such as epinephrine, sclerosants, thrombogenic substances, or thermal therapies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy involving injection and thermal techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meta-analyses of controlled trials
Number of subjects: 0
Study: 8866311

Group type: EXPERIMENTAL
Intervention: KCl/MFP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: NaMFP
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: SrAc2F
Number of subjects: 56
Study: 1627020

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 3796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3796
Study: 6375465

Group type: EXPERIMENTAL
Intervention: 0.15 mg buprenorphine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 0.3 mg buprenorphine
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 0.3 mg buprenorphine after bupivacaine
Number of subjects: 158

Group type: COMPARATOR
Intervention: Control group (no reinjection)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 158
Study: 31147243

Group type: EXPERIMENTAL
Intervention: Collaborative depression care management intervention
Number of subjects: 2351

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 2351
Study: 29970139

Group type: EXPERIMENTAL
Intervention: HAL training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 19
Study: 25432493

Group type: EXPERIMENTAL
Intervention: Bladder neck plication stitch
Number of subjects: 158

Group type: COMPARATOR
Intervention: No bladder neck plication stitch
Number of subjects: 158
Study: 24370820

Group type: EXPERIMENTAL
Intervention: Group II (lateral position with injected arm down and 20° Trendelenburg position)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Group I (supine position)
Number of subjects: 50
Study: 23023905

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (3 capsules per day: eicosapentaenoic acid 1,548 mg; docosahexaenoic acid 828 mg; other omega-3 fatty acids 338 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo capsules (sunflower oil 2,100 mg)
Number of subjects: 84
Study: 19778673

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) + Optimal medical therapy (OMT)
Number of subjects: 2285

Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT) alone
Number of subjects: 2285
Study: 17536129

Group type: EXPERIMENTAL
Intervention: Blueberry (12.5 mmole Trolox Equivalents (TE) AOC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mixed grape powder (39.9 mmole TE AOC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cherries (280 g, 4.5 mmol TE AOC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control groups with additional macronutrients (Studies #4 and #5)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Dried plums or dried plum juice
Number of subjects: 50
Study: 15132730

Group type: EXPERIMENTAL
Intervention: Nicotinamide (NA) plus Vitamin E
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nicotinamide (NA)
Number of subjects: 64
Study: 11488362

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75-225 mg/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60 mg/day)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 9733153

Group type: EXPERIMENTAL
Intervention: EPA and DHA ethyl esters (2.04 g EPA and 1.4 g DHA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Olive oil (4 g/day)
Number of subjects: 32
Study: 8778189

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cyclosporin
Number of subjects: 27
Study: 2256489

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol (0.035 mg)‐norethindrone (0.40 mg)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol (0.030 to 0.040 mg)‐levonorgestrel (0.050 to 0.125 mg)
Number of subjects: 156

Group type: COMPARATOR
Intervention: non‐oral‐contraceptive group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 156
Study: 582998

Group type: EXPERIMENTAL
Intervention: 1,3,7-trimethyl-xanthine (caffeine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no caffeine)
Number of subjects: 0